Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure

Journal of Infectious Diseases

Volumn 207, Issue 6, 2013, Pages 893-897

  Li, Jonathan Z ^a   Paredes, Roger ^b   Ribaudo, Heather J ^c   Kozal, Michael J ^d   Svarovskaia, Evguenia S ^e   Johnson, Jeffrey A ^f   Geretti, Anna Maria ^g   Metzner, Karin J ^h   Jakobsen, Martin R ⁱ   Hullsiek, Katherine Huppler ^j   Ostergaard, Lars ⁱ   Miller, Michael D ^e   Kuritzkes, Daniel R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Lluita Contra la SIDA Foundation   (Spain)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e GILEAD SCIENCES   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ AARHUS UNIVERSITY   (Denmark)

^j UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

HIV 1 drug resistance; minority variants; resistance genotyping; virologic failure

Indexed keywords

EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COPY NUMBER VARIATION; DRUG TREATMENT FAILURE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; RACE DIFFERENCE;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; DRUG RESISTANCE, VIRAL; FEMALE; GENE DOSAGE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MULTIVARIATE ANALYSIS; MUTATION; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE;

EID: 84874253319     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis925     Document Type: Article

References (21)

1. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993; 365:671-3.
2. Church JD, Jones D, Flys T, et al. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn 2006; 8:430-2; quiz 527.
3. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011; 305:1327-35.
4. Tsibris AM, Korber B, Arnaout R, et al. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS ONE 2009; 4:e5683.
5. Codoner FM, Pou C, Thielen A, et al. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Res 2010; 88:281-6.
6. Liu J, Miller MD, Danovich RM, et al. Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. Antimicrob Agents Chemother 2011; 55:1114-9.
7. Halvas EK, Wiegand A, Boltz VF, et al. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J Infect Dis 2010; 201:672-80.
8. Paredes R, Lalama CM, Ribaudo HJ, et al. Preexisting minority drugresistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010; 201:662-71.
9. Simen BB, Simons JF, Hullsiek KH, et al. Low-abundance drugresistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009; 199:693-701.
10. Jakobsen MR, Tolstrup M, Sogaard OS, et al. Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. Clin Infect Dis 2010; 50:566-73.
11. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008; 5:e158.
12. Geretti AM, Fox ZV, Booth CL, et al. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 52:569-73.
13. Metzner KJ, Giulieri SG, Knoepfel SA, et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatmentnaive and-adherent patients. Clin Infect Dis 2009; 48:239-47.
14. Goodman D, Zhou Y, Margot NA, et al. Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatmentnaive individuals undergoing efavirenz-containing therapy. AIDS 2011; 25:325-33.
15. Iglesias-Ussel MD, Casado C, Yuste E, Olivares I, Lopez-Galindez C. In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J Gen Virol 2002; 83:93-101.
16. Hanna GJ, Johnson VA, Kuritzkes DR, et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000; 181:904-11.
17. Ngo-Giang-Huong N, Jourdain G, Amzal B, et al. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis. PLoS One 2011; 6:e27427.
18. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008; 197:867-70.
19. Weintrob AC, Grandits GA, Agan BK, et al. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr 2009; 52:574-80.
20. Ribaudo H, Smith K, Robbins GK, et al. Race differences in the efficacy of initial ART on HIV infection in randomized trials undertaken by ACTG. In: 18th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, Feb 27-Mar 2, 2011 (abstract 50).
21. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42:401-7.